Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia

Authors

Rino Alvani Gani, Divisi Hepatobilier, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/Rumah Sakit Pusat Nasional Cipto Mangunkusumo, Jakarta, Indonesia.Follow

Abstract

Introduction. Tenofovir disoproxil fumarate (tenofovir) and telbivudine are two available nucleos(t)ide analogue (NA) for the treatment of chronic hepatitis B (CHB) patients. Tenofovir has been known as a nephrotoxic agent in HIV patients, but still controversy in CHB patients. On the other hand, telbivudine had a renal protective effect and increased estimated glomerular filtration rate (eGFR). This studi aimed to address the renal safety of tenofovir and telbivudine in Indonesian patients. Method. A retrospective cohort study design was conducted in CHB patients who prescribed with tenofovir or telbivudine from January 2013 to December 2016. Patients who hade baseline eGFR

Recommended Citation

Gani, Rino Alvani (2018) "Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia," Jurnal Penyakit Dalam Indonesia: Vol. 5: Iss. 3, Article 5.
DOI: 10.7454/jpdi.v5i3.213
Available at: https://scholarhub.ui.ac.id/jpdi/vol5/iss3/5